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Objectives: Most industrialized countries strive to guarantee long term sustainabil-
ity for HIV antiretroviral treatment . By assessing the most relevant current predictors 
of costs of antiretrovirals(HAART) might represent the first step to understand spend-
ing drivers and to plan cost reduction strategies. MethOds: A retrospective sample 
of HIV outpatients followed at 5 Italian Hospitals in 2012 was collected. Demographic 
features, current HIV viral load, current and Nadir CD4 T-celI counts, time from HIV 
diagnosis, AIDS-defining events, HAART line and HCV coinfection were taken into 
consideration. Individual ARV regimen-costs were based on local pharmacy data-
sets from December, 2011, and log-transformed in the final multivariate models. 
Univariate analyses were performed to identify potential predictors and stepwise 
multivariate regressions were used to identify independent predictors of higher indi-
vidual costs, using Stata 10.1 package. Results: We included 2044 patients, 69.0% 
males, mean age 47.2±10.0 years; 33.4% HCV-coinfected, mean time from HIV diag-
nosis 13.3±7.9 years, mean nadir CD4 T cell counts 239±169.3 cell/mm3; mean current 
CD4T-cell counts 590±302.6 cell/mm3, 30.8% AIDS classified. Patients on HAART were 
1,902 (93.0%),among treated patients, 19.0% presented an HIV-viremia> 50 c/mL. Mean 
annual individual HAART-costs were € 9,376±3,501 (782-29,852). At univariate analysis, 
a significant association was found between costs and age time from HIV diagno-
sis, previous AIDS diagnosis, HCV-coinfection current and Nadir CD4T-cell counts, 
HAART-line, HIV-viremia and site of care. In the final regression model, HAART costs 
showed independent and direct correlation with HAART lines (p< 0.001), detectable 
viremia (p< 0.001) and time from HIV diagnosis (p= 0.009); inverse correlation with 
Nadir CD4 T-cell counts (p= 0.01). Being treated at 2 of 5 centre was another predictor of 
higher costs.(P< 0.001). cOnclusiOns: Higher HAART-costs were strongly associated 
with previous treatment failures and detectable HIV-viremia; a more compromised 
immune status at clinical presentation and a longer duration of HIV infection showed 
independent contribution, focusing on timely diagnosis of HIV infection.
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Objectives: Develop model simulating economic implications of alternative treat-
ment strategies for acute bacterial skin and skin structure infections (ABSSSIs) 
with suspected Methicillin-Resistant Staphylococcus aureus (MRSA) that consid-
ers antibiotic switches, course duration, route of administration and location of 
care (LOC). MethOds: Discrete event simulation (DES) tracks patient pathways 
through various LOC (ED, inpatient, outpatient) during ABSSSI treatment for sus-
pected MRSA. Model assumes 60% of patients hospitalized. Multiple pathways are 
allowed: patients responding can move to outpatient to finish treatment, switch 
treatment at discharge or receive 2nd line treatment if not responding. Patients 
accrue resource use, time in LOC and costs. Hospital days obtained from analysis 
of Premier Hospital Database. Three cohorts created; all assigned to receive van-
comycin (VAN) 1st line therapy. Upon discharge, one cohort continued on VAN, one 
switched to oral linezolid (LIN), one to daptomycin (DAP) to complete treatment. 
Costs are from the Medicare perspective in 2012 USD. Results: Hospital plus out-
patient days range from 11.1 (VAN) to 14.5 (LIN); costs ranged from $6,983 (LIN) 
to $8,122 (VAN) with suspected MRSA. By comparison, reatment duration ranged 
from 9.97 (VAN) to 13.02 (LIN) and total costs ranged from $6,889 (LIN) to $9,354 
(VAN) when MRSA is not always suspected. Despite longer LIN treatment, costs are 
lower because of avoided infusion costs. Outpatient costs account for 22% (LIN) to 
33% (VAN) of total costs. Sensitivity analysis examined impact on cost when treat-
ment duration varied per drug labeling. Total costs varied from $6,756 to $7,158 
when duration of LIN ranges from 8 days to 12 days. cOnclusiOns: Treatment 
choice and LOC have major impact on ABSSSI resource use and costs. Suspected 
MRSA increases treatment duration and cost. Economic implications for payers and 
providers should be evaluated using models that capture these elements in view 
of long-acting lipoglycopeptide IV antibiotics in development that avoid repeated 
infusions and may allow for less inpatient treatment.
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Objectives: Adverse events (AEs) and premature treatment discontinuation of pro-
tease inhibitor (PI) therapy in the treatment of chronic hepatitis C (CHC) may mitigate 
the benefits of improved sustained virologic response. We use data from a recent study 
to estimate the economic impact of PI therapy in the cirrhotic non-responder popula-
tion. MethOds: In the Compassionate Use of Protease Inhibitors in viral C cirrhosis 
(CUPIC) study, patients with compensated cirrhosis and genotype 1 CHC were treated 
with boceprevir (n= 205) or telaprevir (n= 292) in combination with peginterferon alpha 
and ribavirin. The investigators reported safety and tolerability in an interim 16-week 
analysis. Using CUPIC data and micro-costing technique, we estimate the costs of treat-
ment-related hematologic and rash AEs by severity (Grades 2-4) and the cost of drug 
wastage using PI discontinuation rates due to serious AEs (SAEs) (7.3% boceprevir; 14.7% 
telaprevir). We surveyed 3 hepatologists to ascertain treatment patterns related to AEs 
and combined these estimates with cost data to compute mean costs per treatment 
group from the US payer perspective during the first 16 weeks of therapy. Results: The 
AE-related costs were $1,980 and $2,161 for telaprevir and boceprevir treated patients, 
respectively, for the first 28 days of treatment. Medication-related costs of premature 
discontinuation due to SAEs were estimated at $8,463 for telaprevir and $1,575 for 
visits, hospitalization days and costs associated with adverse events, which included 
medical services and medications. Results: The study included 1,081 patients who 
used at least one HCV medication (mean age of 46.4 years [SD= 10.7], 64.8% men). 
Peg-Riba only, Peg-Riba+boceprevir and Peg-Riba+telaprevir was used by 1,029 (95.2%), 
50 (4.6%) and 18 (1.7%) patients respectively. Fifty-seven patients (5.3%) required a 
subsequent HCV treatment during the study period. The mean duration of treatments 
was 30.4 weeks (SD= 16.1). During HCV treatment, the average number of health care 
resources per patient was 13.2 physician’s visits and procedures, 1.0 hospitalization 
day and 0.9 emergency visit. While receiving HCV treatment, 191 (17.7%) of patients 
required erythropoietin, 353 (32.7%) received rash treatments and 541 (50.0%) were 
treated for depression. Estimated costs associated with management of these three 
AE were CDN$10,834, CDN$78 and CDN$268 per patient respectively. cOnclusiOns: 
HCV treatment is associated with significant health care resource utilization. A high 
proportion of patients experienced AE for which management was associated with 
substantial additional costs, especially the anemia treatment. Thus, the cost of AE 
should be considered in future treatment options.
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Objectives: Genital warts (GW), 90% of which are caused by human papillomavirus 
(HPV) types 6 and 11, are a significant problem in the UK. The cost of managing GW 
in 2010 was previously estimated at £52.4 million. The objective of this study was 
to estimate the cost of GW management up to 2012, and to determine the cost by 
UK jurisdiction. MethOds: Population statistics were obtained from the Office of 
National Statistics for the UK, England and Wales; the General Register Office and 
2011 census data for Scotland; and the Northern Ireland (NI) Statistics and Research 
Agency. Numbers of GW cases in genito-urinary medicine (GUM) clinics were 
obtained from the Health Protection Agency for the UK and England; the Information 
Services Division for Scotland; the Communicable Disease Surveillance Centre for 
Wales; and the Public Health Agency for NI. The number of cases treated in primary 
care was estimated from The Health Improvement Network database. Population 
statistics and GW cases were extrapolated by jurisdiction to 2012. The number of 
visits and therapy required for GW management were estimated by GUM experts 
for standard and hard-to-treat patients. Costs were obtained from the most recent 
National Health Service (NHS) Payment by Results tariffs, Personal Social Services 
Research Unit and British National Formulary. Results: The model estimated 
220,779 GW cases in the UK, costing £58.42 million annually (£265 per patient). For 
England, 157,693 cases were estimated costing £41.72 million; for Scotland 7,461 
cases costing £1.90 million; for Wales 7,091 cases costing £1.87 million; and for NI 
3,619 cases costing £0.95 million. cOnclusiOns: The full NHS costs for the man-
agement of GW have never before been estimated separately for each jurisdiction. 
The results of the model reveal a significant economic burden which is important 
to quantify when understanding the value of quadrivalent HPV vaccination.
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Objectives: The ANRS CO20-CUPIC study was designed to evaluate triple therapy 
(TT) efficacy and safety in HCV-cirrhosis treatment-experienced patients in the 
French Early Access Programme. A 60-week interim analysis has been reported 
confirming better clinical outcomes than double therapy in a real clinical setting. 
However, independently of the protease inhibitor (PI) used, boceprevir (BOC) or tel-
aprevir (TLV), treatment failure (TF) was reported in up to 60% of the patients. Little 
is known about these patients’ treatment cost: that of successfully treated patients 
can be generally calculated from the full course of PI treatment, but the cost of those 
who failed highly depends on TF timing. Our objective is to estimate the average PI 
cost/patient who failed treatment based on CUPIC study reported data. MethOds: 
Using reported data on ITT virological response and TF, BOC and TLV on-treatment 
rates over time were estimated. Based on this curve, the average PI treatment duration 
and average PI cost/patient who failed treatment were calculated. When not enough 
information about time to treatment discontinuation was available, the same con-
servative approach was applied for both drugs, considering the midpoint of the treat-
ment interval. Sensitivity analyses on the time to TF were performed to confirm the 
robustness of the results. Results: A total of 472 patients (72%) were included in the 
60-week interim analysis. Independently of the IP used, about 60% the patients who 
start treatment did not achieve viral cure and their estimated average PI treatment 
duration was 26 wks in BOC patients and 11 wks in TLV patients. The average PI cost/
patient who failed treatment with TLV (23.012€ ) was 26% higher than that of treatment 
with BOC (18.253€ ). The sensitivity analysis confirmed the robustness of the base case 
estimation. cOnclusiOns: In a scenario of comparable efficacy between both PIs, 
the resources wasted on TF acquire a great importance in selecting the least costly of 
the two alternatives. Based on CUPIC study reported data, the average PI cost/patient 
who failed treatment was significantly higher in TLV patients than in BOC patients.
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